Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585514 | 0.86 | CHRM5 (0.33) | NMT1CYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL10872330 | 0.80 | ALDH1A1 (0.53) | NMT1CYP3A4ALDH1A1TDP1HPGD | |
| SCHEMBL793988 | 0.79 | NMT1 (0.38) | NMT1ALDH1A1TDP1LMNAKMT2A | |
| SCHEMBL31619139 | 0.79 | CYP3A4 (0.38) | CYP3A4ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL3208926 | 0.79 | CYP3A4 (0.38) | CYP3A4ALDH1A1TDP1TSHRLMNA | |
| SCHEMBL14956328 | 0.79 | NMT1 (0.38) | NMT1ALDH1A1TDP1LMNAKMT2A | |
| SCHEMBL26234359 | 0.77 | NMT1 (0.37) | NMT1ALDH1A1TDP1LMNAKMT2A | |
| SCHEMBL29745432 | 0.75 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL528819 | 0.75 | TSHR (0.40) | NMT1CYP3A4ALDH1A1TDP1HPGD | |
| SCHEMBL29227282 | 0.75 | GRIN2D (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117658763-A | Preparation method of 5-bromo-1, 2-dichloro-3-fluorobenzene | 棓诺(苏州)新材料有限公司 | 2024-03-08 | — | — | CN | claimed |
| US-20260022100-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2026-01-22 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4545517-A1 | NAV1.8 INHIBITOR | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-04-30 | — | — | EP | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240246979-A1 | cGAS INHIBITORS | ELI LILLY AND COMPANY | 2024-07-25 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117658763-A | Preparation method of 5-bromo-1, 2-dichloro-3-fluorobenzene | 棓诺(苏州)新材料有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117658763-A | Preparation method of 5-bromo-1, 2-dichloro-3-fluorobenzene | 棓诺(苏州)新材料有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117658763-A | Preparation method of 5-bromo-1, 2-dichloro-3-fluorobenzene | 棓诺(苏州)新材料有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2009-12-24 | — | — | US | disclosed |
| WO-2009153178-A2 | ARYL KETONE AS MRI | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153178-A2 | ARYL KETONE AS MRI | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-2102157-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008074703-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074703-A1 | HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | NMT1 1169/4885CYP3A4 4653/4885ALDH1A1 4838/4885 |
| US-20080146607-A1 | Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | CNKSR1, RB1, AR | NMT1 4354/4885CYP3A4 123/4885ALDH1A1 447/4885 |
| US-20260022100-A1 | NAV1.8 INHIBITOR | SCN8A, SCN1B, SCN1A | NMT1 462/4885CYP3A4 700/4885ALDH1A1 853/4885 |
| US-20090318493-A1 | Aryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof | TPH2, TPH1, ADRA2C | NMT1 3755/4885CYP3A4 292/4885ALDH1A1 861/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | NMT1 1417/4885CYP3A4 3438/4885ALDH1A1 4861/4885 |
| US-20240246979-A1 | cGAS INHIBITORS | CGAS, STING1, IRF3 | NMT1 1348/4885CYP3A4 3788/4885ALDH1A1 4299/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | NMT1 1169/4885CYP3A4 4653/4885ALDH1A1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.